Research blog: Accelerating progress in AML
Since 2017, the FDA has approved 12 new treatments for AML, with more on the horizon.
This blog reviews breakthroughs in AML treatment, highlighting FDA approval of 12 new therapies—including venetoclax, FLT3 and IDH1/2 inhibitors—as well as emerging menin inhibitors and immunotherapies, and stressing the need for ongoing clinical trials to personalize care.
AML is a rapidly progressing, high‑mortality blood cancer; new therapeutic options and clinical trials offer hope for improved survival, especially in high‑risk genetic subtypes such as TP53‑mutated AML.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Management of Acute Myeloid Leukemia: A Review
- Old cells, new tricks—important clue to AML diagnosis and cure discovered
- Treatment of Acute Myeloid Leukaemia
- Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates
- Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012